{"entity":{"id":"paper-galleri-real-world-nat-commun-2025","kind":"paper","name":"Real-world data and clinical experience from over 100,000 multi-cancer early detection tests","aka":[],"tldr":"Across 111,080 Galleri tests ordered in ordinary US practice, about one in a hundred was positive, and where doctors reported back, just over half of those people had cancer.","summary":"Matrana and colleagues analysed 111,080 people (median age 58) who had the Galleri test commercially. The cancer signal detection rate was 0.91% (1,011 of 111,080). Providers reported a clinical outcome for 459 of the 1,011; 258 of these had an invasive cancer diagnosis across 32 cancer types. Cancer signal origin was correct in 87% of cases with a reported cancer type, and the median time from result to diagnosis was 39.5 days.","asOf":"2026-10-29","links":[{"label":"Nature Communications 2025","url":"https://doi.org/10.1038/s41467-025-64094-7"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/41173830/"}],"tags":[],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["mced"],"targets":[],"drugs":["galleri"],"companies":["grail"],"institutions":[],"pathways":[],"terms":["ppv"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-communications"],"dependsOn":[],"notes":[],"journal":"Nature Communications","year":2025,"doi":"10.1038/s41467-025-64094-7","pmid":"41173830","authors":"Matrana M, Shukla V, Kingsbury D, et al.","paperType":"real-world","findings":["Signal detected in 0.91% (1,011 of 111,080).","Outcome reported for 459 of 1,011 positives; 258 had invasive cancer.","Cancer signal origin correct in 87%; median 39.5 days to diagnosis."],"whatItMeans":"Outcomes are known for fewer than half of the positives, so the share of positives that were cancer in this group cannot be read as the test's positive predictive value, and cancers missed by the test are not counted at all.","caveats":["Outcome data for only 459 of 1,011 positive results; none for negatives.","Self-selected paying customers, not a screening population.","Authors include GRAIL staff."],"changedPractice":false,"participants":111080},"route":"/key-papers/paper-galleri-real-world-nat-commun-2025/","neighbours":{"section":[{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}],"drug":[{"id":"galleri","kind":"drug","name":"Galleri","route":"/drugs/galleri/"}],"company":[{"id":"grail","kind":"company","name":"GRAIL","route":"/companies/grail/"}],"term":[{"id":"ppv","kind":"term","name":"Positive predictive value (PPV)","route":"/terms/ppv/"}],"journal":[{"id":"nature-communications","kind":"journal","name":"Nature Communications","route":"/journals/nature-communications/"}]}}